The CEO of UK based Levicept shares background on the company's neurotrophin-3 inhibiting fusion protein, which they say succeeded today in pain management in an osteoarthritis phase 2 study
- blonca9
- Aug 6, 2024
- 1 min read
Eliot Forster describes the scientific rational of inhibiting NT-3 while avoiding nerve growth factor and the side effects that come with it.